Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS11D | O60235 | 12/20 | 0.73 |
| ▸ | F2 | P00734 | 11/20 | 0.73 |
| ▸ | F10 | P00742 | 4/20 | 0.73 |
| ▸ | PLG | P00747 | 3/20 | 0.73 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.52 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.52 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1416490 | 0.91 | TMPRSS11D (0.61) | TMPRSS11DF2F10PLGPRSS1 | |
| SCHEMBL23135065 | 0.88 | TMPRSS11D (0.74) | TMPRSS11DF2F10PLGPRSS1 | |
| SCHEMBL13554420 | 0.86 | TMPRSS11D (0.73) | TMPRSS11DF2F10PLG | |
| SCHEMBL12514170 | 0.86 | TMPRSS11D (0.72) | TMPRSS11DF2F10PLG | |
| SCHEMBL12514561 | 0.84 | TMPRSS11D (0.69) | TMPRSS11DF2F10PLG | |
| SCHEMBL7106028 | 0.83 | TMPRSS11D (0.68) | TMPRSS11DF2F10PLG | |
| Hydrochloric Acid SCHEMBL7140902 | 0.82 | TMPRSS11D (0.67) | TMPRSS11DF2F10PLG | |
| SCHEMBL7365085 | 0.81 | TMPRSS11D (0.64) | TMPRSS11DF2F10PLG | |
| SCHEMBL7353953 | 0.81 | TMPRSS11D (0.65) | TMPRSS11DF2F10PLG | |
| SCHEMBL16181254 | 0.81 | F2 (0.52) | TMPRSS11DF2F10PLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120270807-A1 | MACROCYCLIC INHIBITORS OF SERINE PROTEASE ENZYMES | TRANZYME PHARMA INC. (CA) | 2012-10-25 | — | — | US | disclosed |
| US-20120270769-A1 | METHODS OF USING MACROCYCLIC INHIBITORS OF SERINE PROTEASE ENZYMES | TRANZYME PHARMA INC. (CA) | 2012-10-25 | — | — | US | disclosed |
| US-8129547-B2 | Anticoagulation of human blood ex vivo | HELLSTERN PETER (DE) | 2012-03-06 | — | — | US | disclosed |
| US-8129547-B2 | Anticoagulation of human blood ex vivo | HELLSTERN PETER (DE) | 2012-03-06 | — | — | US | disclosed |
| WO-2011050270-A2 | MACROCYCLIC INHIBITORS OF SERINE PROTEASE ENZYMES | TRANZYME PHARMA, INC. (US) | 2011-04-28 | — | — | WO | disclosed |
| US-20100280412-A1 | Anticoagulation Of Human Blood Ex Vivo | HELLSTERN PETER | 2010-11-04 | — | — | US | disclosed |
| US-20100280412-A1 | Anticoagulation Of Human Blood Ex Vivo | HELLSTERN PETER | 2010-11-04 | — | — | US | disclosed |
| EP-1973929-B1 | ANTICOAGULATION OF HUMAN BLOOD EX VIVO | HELLSTERN PETER (DE) | 2010-09-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270769-A1 | METHODS OF USING MACROCYCLIC INHIBITORS OF SERINE PROTEASE ENZYMES | PRSS1, SPINT2, TMPRSS15 | TMPRSS11D 9/4885F2 145/4885F10 435/4885 |
| US-20100280412-A1 | Anticoagulation Of Human Blood Ex Vivo | F5, TFPI, F11 | TMPRSS11D 496/4885F2 13/4885F10 9/4885 |
| US-20120270807-A1 | MACROCYCLIC INHIBITORS OF SERINE PROTEASE ENZYMES | PRSS1, SPINT2, SERPINB1 | TMPRSS11D 8/4885F2 152/4885F10 429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.